【作者】Shao, Shan;Li, Su;Qin, Youwen;Wang, Xiaorui;Yang, Yining;Bai, Haitao;Zhou, Lili;Zhao, Chuxian;Wang, Chun
【出处】INTERNATIONAL JOURNAL OF ONCOLOGY
【年份】2014
【卷号】Vol.44 No.5
【页码】1661-1668
【ISSN】1019-6439
【分类号】616.99
【摘要】Imatinib mesylate (IM), a targeted competitive inhibitor of the BCR-ABL tyrosine kinase, has revolutionized the clinical treatment of chronic myeloid leukemia (CML). However, resistance and intolerance are still a challenge in the treatment of CML. Autoph
